Regulatory Compliance Update
Lupin Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey. The inspection resulted in a satisfactory Voluntary Action Indicated (VAI) classification.
Inspection Details
- Inspection Dates: April 13, 2026 to April 17, 2026
- Facility Location: Somerset, New Jersey, USA
- Regulatory Outcome: Voluntary Action Indicated (VAI) classification
- Report Type: Establishment Inspection Report (EIR)
Management Commentary
Nilesh Gupta, Managing Director of Lupin, stated: "We are pleased to receive the EIR with a VAI classification from the U.S. FDA for our Somerset facility. This outcome reflects our unwavering commitment to quality, compliance, and operational excellence, and reinforces our dedication to manufacturing high-quality medicines that patients around the world can trust."
Company Background
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in:
- Branded and generic formulations
- Complex generics
- Biotechnology products
- Active pharmaceutical ingredients
Operational Scale
- Manufacturing Sites: 15 state-of-the-art facilities globally
- Research Centers: 7 global research centers
- Workforce: Over 24,000 professionals
- Key Therapy Areas: Respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health
Subsidiary Operations
The company operates through subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Disclosure Context
This announcement is made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as required for material events affecting listed companies.